Association between the C-reactive protein–triglyceride–glucose index and coronary heart disease in metabolic dysfunction-associated steatotic liver disease patients: a cross-sectional study - Report - MDSpire
Advertisement
Association between the C-reactive protein–triglyceride–glucose index and coronary heart disease in metabolic dysfunction-associated steatotic liver disease patients: a cross-sectional study
Clinical Report: Link Between CTI and Coronary Heart Disease in MASLD Patients
Overview
This study investigates the association between the C-reactive protein–triglyceride–glucose index (CTI) and coronary heart disease (CHD) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
Background
Coronary heart disease (CHD) is a significant public health concern, particularly in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), which affects over 30% of adults globally. Identifying effective biomarkers for assessing CHD risk in this population is crucial.
Data Highlights
Measure
Value
Patients with CHD
387 (63.3%)
Odds Ratio for CTI and CHD
2.48 (95% CI 1.69–3.63, P < 0.001)
AUC for CTI
0.845 (95% CI 0.815–0.876)
Key Findings
CTI is associated with the presence of CHD in MASLD patients.
Higher CTI levels correspond to greater severity of coronary stenosis.
The association between CTI and CHD is stronger in patients aged ≥55 years.
CTI demonstrates better discriminative ability for CHD compared to other insulin resistance indices.
Clinical Implications
The findings indicate that CTI may be relevant for assessing CHD risk in patients with MASLD.
Conclusion
The study highlights the association between CTI and CHD in MASLD patients.
